Skip to main content
Livermore
Livermore
ZHEN

Propel Bio Management, LLC

SEC CIK
0001969764
Latest filing
Aug 13, 2026

Holdings in Q1 2026

Holdings as of Mar 31, 2026, filed May 14, 2026. Long positions only; changes compare share counts with Q4 2025.

Institution overview
Positions
38
+18 vs. Q4 2025
Portfolio value
$158.7M
+$41.5M (+35.5%) vs. Q4 2025
Filed
May 14, 2026
SEC
Holdings of Propel Bio Management, LLC in Q1 2026
SecurityClassSharesValue% of portfolioShare changeActionHistory
PAGPPlains GP Holdings LPLTD PARTNR INT A1,272,360$30.2M19.0%00.0%UnchangedHistory
ACHVAchieve Life Sciences, Inc.COM3,786,425$11.4M7.2%00.0%UnchangedHistory
PHATPhathom Pharmaceuticals, Inc.COM841,272$9.35M5.9%+100,354+13.5%AddedHistory
DCTHDelcath Systems, Inc.COM NEW979,698$9.16M5.8%+541,189+123.4%AddedHistory
CORTCorcept Therapeutics IncCOM147,828$6.02M3.8%+147,828NewHistory
ABEOAbeona Therapeutics Inc.COM NEW1,329,899$6.01M3.8%+499,119+60.1%AddedHistory
VORVor Biopharma Inc.COM NEW314,543$5.59M3.5%+314,543NewHistory
KYTXKyverna Therapeutics, Inc.COM644,421$5.59M3.5%−22,245−3.3%ReducedHistory
MISTMilestone Pharmaceuticals Inc.COM4,118,321$5.08M3.2%00.0%UnchangedHistory
CLDXCelldex Therapeutics, Inc.COM NEW131,364$4.14M2.6%−22,936−14.9%ReducedHistory
CMPSCOMPASS Pathways plcSPONSORED ADS742,049$4.12M2.6%−119,729−13.9%ReducedHistory
VRDNViridian Therapeutics, Inc.COM210,163$4.09M2.6%−72,368−25.6%ReducedHistory
IVAInventiva S.A.ADS724,678$3.99M2.5%−275,322−27.5%ReducedHistory
SABSSAB Biotherapeutics, Inc.COM NEW1,012,790$3.89M2.4%+359,909+55.1%AddedHistory
OBIOOrchestra BioMed Holdings, Inc.COM896,701$3.83M2.4%+896,701NewHistory
FDMT4D Molecular Therapeutics, Inc.COM380,420$3.58M2.3%+380,420NewHistory
OCSOculis Holding AGORDINARY SHARES122,223$3.28M2.1%−50,616−29.3%ReducedHistory
OCULOcular Therapeutix, IncCOM382,375$3.23M2.0%+382,375NewHistory
UPBUpstream Bio, Inc.COM341,779$3.10M2.0%+341,779NewHistory
AQSTAquestive Therapeutics, Inc.COM710,988$2.95M1.9%+710,988NewHistory
EYPTEyePoint, Inc.COM NEW215,825$2.79M1.8%+215,825NewHistory
TRVITrevi Therapeutics, Inc.COM223,802$2.65M1.7%+223,802NewHistory
ZVRAZevra Therapeutics, Inc.COM NEW282,418$2.64M1.7%+218,735+343.5%AddedHistory
IMUXImmunic, Inc.COM2,344,779$2.62M1.7%+2,344,779NewHistory
CHRSCoherus Oncology, Inc.COM1,420,550$2.41M1.5%+1,420,550NewHistory
OVIDOvid Therapeutics Inc.COM921,457$2.04M1.3%+921,457NewHistory
PALIPalisade Bio, Inc.COM1,115,000$2.00M1.3%+1,115,000NewHistory
KLRSKalaris Therapeutics, Inc.COM295,771$1.72M1.1%+253,718+603.3%AddedHistory
QUREuniQure N.V.SHS104,772$1.71M1.1%+104,772NewHistory
LONALeonaBio, Inc.COM149,279$1.50M0.9%00.0%UnchangedHistory
NUVBNuvation Bio Inc.COM CL A329,296$1.41M0.9%+329,296NewHistory
MAZEMaze Therapeutics, Inc.COM43,798$1.31M0.8%+43,798NewHistory
EVMNEvommune, Inc.COM SHS55,664$1.28M0.8%+55,664NewHistory
CRVSCorvus Pharmaceuticals, Inc.COM85,791$1.25M0.8%+85,791NewHistory
ALDXAldeyra Therapeutics, Inc.COM730,606$1.23M0.8%+730,606NewHistory
ARTVArtiva Biotherapeutics, Inc.COM146,369$949.8K0.6%+146,369NewHistory
CNTBConnect Biopharma Holdings LtdSHS209,493$553.9K0.3%+209,493NewHistory
MSLESatellos Bioscience Inc.COM10,145$57.1K<0.1%+10,145NewHistory

Sold out since Q4 2025 (4)

Positions held at the end of Q4 2025 that are gone from this filing.

Positions of Propel Bio Management, LLC sold out since Q4 2025
SecurityClassShares in Q4 2025Value in Q4 2025% of portfolio in Q4 2025History
NKTRNektar TherapeuticsCOM NEW82,822$3.50M3.0%History
RGNXREGENXBIO Inc.COM116,896$1.68M1.4%History
LENZLENZ Therapeutics, Inc.COM59,085$945.4K0.8%History
AARDAardvark Therapeutics, Inc.COM46,408$609.1K0.5%History